(C) Reuters. Portugal resumes AstraZeneca vaccination after temporary suspension
(Reuters) – British drugmaker AstraZeneca (NASDAQ:AZN) Plc may have included outdated information from its COVID-19 vaccine clinical trial, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) said on Tuesday.
The Data and Safety Monitoring Board has notified the drugmaker, NIAID and the Biomedical Advanced Research and Development Authority that it was concerned by the information released by AstraZeneca on the initial data from its clinical trial, according to a statement from the NIAID.
AstraZeneca may have included outdated info from U.S. vaccine trial: NIAID
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.